YZY Biopharma

Executive Summary

YZY Biopharma is a clinical-stage biotechnology company based in Shanghai, China, focused on developing novel bispecific antibody therapeutics for oncology and immunology. Founded in 2020, the company leverages its proprietary platform to create next-generation T-cell engagers and immune modulators targeting challenging cancers and autoimmune diseases. With $50 million raised to date and a phase-1 stage pipeline, YZY is positioned in the competitive bispecific antibody space, though specific pipeline details are not publicly disclosed. The company's early-stage nature and reliance on innovative biologic approaches present both opportunity and risk, as clinical validation is pending.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Clinical Data Readout for Lead Bispecific Candidate50% success
• Q3 2026Potential Strategic Partnership or Licensing Deal40% success
• TBDNext Financing Round (Series B or C)60% success